Management of Idiopathic Pulmonary Fibrosis

Introduction to Treatment

The American Thoracic Society and the European Respiratory Society recommend against the use of corticosteroids for chronic management of IPF due to increased mortality compared to placebo, except during acute exacerbations 1, 2, 3
The American College of Rheumatology/American College of Chest Physicians guidelines provide recommendations for steroid use in different SARD-ILDs, including a strong recommendation against glucocorticoids as first-line treatment for Systemic Sclerosis (SSc)-ILD, with preferred therapy being Mycophenolate and alternative options including Tocilizumab and cyclophosphamide 4

For Sjögren's-associated ILD, the CHEST consensus guidelines recommend moderate-dose oral corticosteroids (up to 60 mg daily prednisone with slow taper over weeks-months) for moderate-severe disease, and pulse-dose IV corticosteroids or high-dose oral prednisone (up to 60 mg daily) for rapidly progressive ILD or respiratory failure, with a steroid-sparing strategy of adding mycophenolate or azathioprine as first-line steroid-sparing agents 5
For other SARD-ILDs, such as Myositis, Mixed Connective Tissue Disease, Rheumatoid Arthritis, and Sjögren's, short-term glucocorticoids (defined as ≤3 months) are recommended, with preferred therapy being Mycophenolate with short-term steroids and alternative options including Azathioprine, cyclophosphamide, and JAK inhibitors (for myositis) 4
Moderate-severe disease may be treated with prednisone 0.5-0.75 mg/kg/day (typically 40-60 mg daily) 5, 6

Response monitoring should include pulmonary function tests every 3-6 months, total serum IgE every 6-8 weeks (for ABPA-related ILD), and clinical parameters (dyspnea, exercise tolerance) 7
Adverse effects to monitor include hyperglycemia, hypertension, osteoporosis, adrenal suppression, increased risk of infections, and psychiatric effects (mood changes, mania) 7
Baseline steroid use may decrease the efficacy of immune checkpoint inhibitors in patients with thoracic malignancies 8

First-line steroid-sparing agents include mycophenolate and azathioprine 4
For patients dependent on oral corticosteroids, itraconazole (for ABPA-related ILD) may be considered 7
For progressive disease despite steroids, rituximab, cyclophosphamide, or nintedanib may be considered 4

The European Respiratory Society and the American Thoracic Society recommend pirfenidone for mild-to-moderate idiopathic pulmonary fibrosis (IPF), with a focus on slowing disease progression and reducing FVC decline 2
Antifibrotic therapy should be the cornerstone of treatment for IPF, with pirfenidone and other agents like nintedanib being used to reduce disease progression, as recommended by the American Thoracic Society 2

The European Respiratory Society recommends long-term oxygen therapy for patients with severe hypoxemia, with a goal of improving oxygenation and reducing symptoms 2
The American Thoracic Society recommends pulmonary rehabilitation for patients with exercise limitation, with a focus on improving functional capacity and quality of life 2
Annual influenza and pneumococcal vaccination is recommended for all patients with pulmonary fibrosis, with a goal of reducing the risk of respiratory infections, as recommended by the European Respiratory Society and the American Thoracic Society 2
Supportive care is essential, including oxygen therapy and management of comorbidities, as emphasized by the American Journal of Respiratory and Critical Care Medicine 3

High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day) are recommended for the treatment of acute exacerbations of usual interstitial pneumonia (UIP), with a gradual taper based on clinical response, as recommended by the European Respiratory Review guidelines 9, 6, 2
Mechanical ventilation should be avoided in most patients with IPF and acute respiratory failure due to high mortality, except in select cases (e.g., bridge to transplant), as recommended by the European Respiratory Review 2
The mortality of acute exacerbation of IPF remains high (~50%) despite treatment, highlighting the need for prompt and effective management, as reported by the American Journal of Respiratory and Critical Care Medicine 3

Clinical parameters should be evaluated after 3 months of therapy, including dyspnea scores, pulmonary function tests, and radiographic findings, as recommended by the European Respiratory Society and the American Thoracic Society 6, 3, 2
Adverse effects related to steroids should be monitored, including hyperglycemia, hypertension, osteoporosis, and suppression of the hypothalamic-pituitary-adrenal axis, as recommended by the European Respiratory Review 9, 3, 2
Consider prophylaxis against Pneumocystis pneumonia for patients receiving prolonged corticosteroid therapy (≥20 mg methylprednisolone or equivalent for ≥4 weeks), and provide calcium and vitamin D supplementation for bone protection, as recommended by the European Respiratory Review 9